NCT05732493 (TORCH-C) is a Phase 2 clinical trial of Serplulimab in Locally Advanced Colon Cancer, sponsored by Fudan University.

Who is sponsoring NCT05732493?

NCT05732493 is sponsored by Fudan University.

What drugs are being tested in NCT05732493?

Interventions in NCT05732493: Serplulimab, short-term radiotherapy, Oxaliplatin, Capecitabine.

What condition does NCT05732493 study?

NCT05732493 studies Locally Advanced Colon Cancer.

Is NCT05732493 still recruiting?

NCT05732493 is currently status unknown. Last updated 17 February 2023.

Last reviewed 2023-02-17 · How we verify

NCT05732493: TORCH-C

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C)

Status unknown Phase 2 Last updated 17 February 2023

What this trial tests

Phase 2 trial testing Serplulimab in Locally Advanced Colon Cancer in 120 participants. Status unknown.

Timeline

1 March 2023

Primary endpoint
31 December 2023

31 December 2024

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	1 March 2023
Primary completion	31 December 2023
Estimated completion	31 December 2024

Drugs / interventions tested

Serplulimab — full drug profile →
short-term radiotherapy
Oxaliplatin (Oxaliplatin) — full drug profile →
Capecitabine (capecitabine) — full drug profile →

Conditions studied

Locally Advanced Colon Cancer — all drugs for Locally Advanced Colon Cancer →

Sponsor

Fudan University

Who can join

18 and older, any sex, with Locally Advanced Colon Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study evaluates the combination of immunotherapy of PD-1 antibody and chemotherapy and neoadjuvant short-course radiotherapy in locally advanced colon cancer (LACC). Patients are randomly assigned into two prospective groups: treatment group and observerment group. In treatment group, a total of 60 patients will receive 5\*5Gy short-course radiotherapy, followed by 4 cycles of capecitabine plus oxaliplatin (CAPOX) chemotherapy and PD-1 antibody, finally receive the surgery. In observerment group: a total of 60 patients will receive 4 cycles of CAPOX chemotherapy, then receive the surgery. The rate of pathologic complete response （pCR）, long-term prognosis and adverse effects will be analyzed.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Study protocol of short-course radiotherapy combined with CAPOX and PD-1 inhibitor for locally advanced colon cancer: a randomised, prospective, multicentre, phase II trial (TORCH-C).
Zhang H, Li Y, Xia F, Sun Y, et al · · 2024 · cited 4× · PMID 38309748 · DOI 10.1136/bmjopen-2023-079442
Study protocol of short-course radiotherapy combined with CAPOX and PD-1 inhibitor for locally advanced colon cancer: a randomized, prospective, multicentre, phase Ⅱ trial (TORCH-C)
Zhang H, Li Y, Xia F, Sun Y, et al · · 2023 · DOI 10.21203/rs.3.rs-2759620/v1

Verify or expand the search:

Other trials of Serplulimab

Trials testing the same drug.

NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07446465 — FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectab · Phase 4 · not yet recruiting
NCT07403435 — Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC · Phase 2 · not yet recruiting
NCT07381400 — Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Stu · Phase 2 · not yet recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05732493 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 17 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05732493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing